Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies-Reference-Cited by-同舟云学术

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies

Published:2013-05-09 Issue:6 Volume:58 Page:327-333
ISSN:1434-5161
Container-title:Journal of Human Genetics
language:en
Short-container-title:J Hum Genet

Author:

Kiyotani Kazuma,Mushiroda Taisei,Zembutsu Hitoshi,Nakamura Yusuke

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Genetics

Link

http://www.nature.com/articles/jhg201339.pdf

Reference97 articles.

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365, 1687–1717 (2005).

2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451–1467 (1998).

3. Wakeling, A. E. & Slater, S. R. Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat. Rep. 64, 741–744 (1980).

4. Mürdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W. et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 708–717 (2011).

5. Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W. & White, I. N. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23, 1897–1901 (2002).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipidome and metabolome analyses reveal metabolic alterations associated with MCF-7 apoptosis upon 4-hydroxytamoxifen treatment;Scientific Reports;2023-10-29

2. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside;ENDOCRINOLOGY;2021

3. Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics;Frontiers in Oncology;2021-11-19

4. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside;Endocrinology;2021-09-04

5. Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM;Journal of Clinical Oncology;2019-08-01